ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Add as a preferred source on Google
On Monday, consumer healthcare firm Haleon announced that U.S. drugmaker Pfizer, its top shareholder, intends to decrease its stake in the company to approximately 24%. Pfizer, holding a 32% stake in Haleon, disclosed plans last year to gradually reduce its ownership over the coming months.
According to Reuters, the offer price per share is expected to be revealed around March 19 following a book-building process.
Financial Implications
The sale of 630 million shares is estimated to be valued at about 2.03 billion pounds ($2.58 billion) based on Haleon's closing price on Friday. Consequently, shares in the FTSE 100-listed company declined by 2.2% to 315 pence in early trading on Monday.
Haleon, renowned for products like Sensodyne toothpaste and Advil painkillers, emerged from the merger of GSK and Pfizer's consumer healthcare divisions in 2019. The company separated from British drugmaker GSK in July 2022.
Ownership Changes
GSK, Haleon's second-largest shareholder, has progressively reduced its stake in the company. In January, GSK's shareholding decreased to 4.2% from the initial 12.9% it retained in the business.
Yahoo reported that Haleon revealed intentions to repurchase shares valued at approximately 315 million pounds from Pfizer outside the market. Furthermore, the London-listed company announced a share buyback scheme worth 500 million pounds this year to meet the rising demand for its products and alleviate debt.
Positive Outlook for Haleon and GSK
Former parent company GSK has seen positive outcomes post the spin-off, surpassing quarterly estimates. It provided an optimistic forecast for 2024 and beyond, benefiting from the growth of its vaccines and cancer drugs pipeline.
Photo: Pfizer Newsroom
